|
|
|
题名
|
作者
|
年代
|
出处
|
被引量
|
| 1 | 非诺贝特治疗与2型糖尿病患者长期心血管病风险的关系显示文摘2型糖尿病患者心血管病风险高,部分原因在于高三酰甘油和低高密度脂蛋白胆固醇血症。而在他汀类药物治疗基础上,加强降低三酰甘油治疗,能否降低这种风险尚不清楚。该研究的目的是在使用他汀类药物治疗的2型糖尿病患者中,确定非诺贝特能否降低心血管病风险。 | 刘莉 叶鹏 Elam MB Ginsberg HN Lovato LC Corson M Largay J Leiter LA Lopez C O'Connor PJ Sweeney ME Weiss D Friedewald WT Buse JB Gerstein HC Probstfield J Grimm R Ismail-Beigi F Goff DC Jr Fleg JL Rosenberg Y Byington RP ACCORDION study investigators | 2017 | 中华高血压杂志2017，25，6： | 7 |
| 2 | 2型糖尿病高血糖的起始和调整治疗共识——美国糖尿病学会和欧洲糖尿病研究协会联合共识显示文摘专家点评:在2005年欧洲糖尿病研究协会(EASD)年会上,国际糖尿病联盟(IDF)颁布了全球首个2型糖尿病治疗指南,我国也发布了自己的指南,然而无论哪个指南,其中主要部分是参考欧美主持的全球多中心临床研究结果。糖尿病药物研究近些年进展迅速,即使在指南的范畴内,仍然有很多选择,令临床医生难以取舍。本文编译介绍了现阶段各种用于2型糖尿病治疗的药物,结合临床研究结果,突出其各自临床应用的优缺点;同时,在药物联合使用和进阶治疗方面,介绍了具体的实施方案和流程,为临床达标治疗的用药选择提供了实用的参考。 | Nathan DM Buse JB Davidson MB 华雪蔚 | 2007 | 世界临床药物2007，28，6： | 3 |
| 3 | Medical management of hyperglycemia in type 2 diabetes:a consensus algorithm for the initiation and adjustment of therapy:a consensus statement of the American Diabetes Association and the European Association for the Study of Diabetes显示文摘 | Nathan DM Buse JB Davidson MB | | Diabetes Care0，，： | 2 |
| 4 | ADA与EASD对2型糖尿病高血糖处理:治疗启动与评定的新共识方案显示文摘在不到一年时间由同一批专家代表ADA和EASD先后起草和发布了两次关于'2型糖尿病高血糖处理的共识声明'同时发表在2008年1月和12月的《Diabetes Care》和《Diabetologia》上。第一次共识声明内容主要围绕TZDs药物的安全性,本刊作了摘译转载(参阅《中国糖尿病杂志》2008年第7期)。第二次修订的共识声明,关注点为降糖药的新分级,论据及观点比较清晰,故仍摘译供读者参考。 | Nathan DM Buse JB Davidson MB Ferrannini E Holman RR Sherwin R Zinman B 钱荣立(摘译) | 2009 | 中国糖尿病杂志2009，17，1： | 2 |
| 5 | Glucagon like peptide l-based therapies for type 2 diabetes: a focus on exenatide显示文摘 | Dungan K Buse JB | 2005 | Clin Diabetes2005，23，： | 1 |
| 6 | Primary prevention of cardiovascular diseases in people with diabetes mellitus: a scientific statement from the American Heart Association and the American Diabetes Association 显示文摘 | Buse JB Ginsberg HN Bakris GL | 2007 | Circulation2007，115，1： | 1 |
| 7 | medical management of hyperglycaemia in type 2 diabetes mellitus:a consensus algorithm for the initiation and adjustment of therapy:a consensus statement from the American Diabetes Association and the European Association for the study of diabete显示文摘 | Nathan DM Buse JB Davidson MB | 2009 | Diabetologia2009，52，： | 1 |
| 8 | Primary Prevention of cardiovascular diseases in PeoPle with diabetes mellitus: A sdentific statement from the American heart association and the American diabetes assodation显示文摘 | Buse JB Ginsberg HN Bakris GL | 2007 | Diabetes care2007，30，： | 1 |
| 9 | Exenatide effects on diabe- tes, obesity, cardiovascular risk factors and hepatic biomarkers in patients with type 2 diabetes treated for at least 3 years显示文摘 | Klonoff DC Buse JB Nielsen LL | 2008 | Curr Med Res Opin2008，24，1： | 1 |
| 10 | Exenatide effects on diabetes, obesity, cardiovascular risk fac tors and hepatic biomarkers in patients with type 2 diabetes treated for at least 3 years 显示文摘 | Klonoff DC Buse JB Nielsen LL | 2008 | CmT Med Res Opin2008，24，： | 1 |
| 11 | Metabolic effects of two years of exenatide treatment on diabetes,obesity,and hepatic biomarkers in patients with type 2 diabetes:an interim analysis of data from the open-label,uncontrolled extension of three double-blind,placebo-controlled trials显示文摘 | Buse JB Klonof DC Nielsen LL | 2007 | Clin Ther2007，29，1： | 1 |
| 12 | Exenatide effects on dia- betes, obesity, cardiovascular risk factors and hepatic biomarkers in patients with type 2 diabetes treated for at least 3 years 显示文摘 | Klonoff DC Buse JB Nielsen LL | 2008 | Curt Med Res Opin2008，24，1： | 1 |
| 13 | A retrospective co- hort study of diabetes mellitus and antipsychotie treatment in the United States 显示文摘 | Buse JB Cavazzon P Hornbuekle K | 2003 | Journal of Clinical Epidemiology2003，56，： | 1 |
| 14 | Hormone replacement therapy in postmenopausal women with schizophrenia: positive effect on negative symptoms? 显示文摘 | Lindamer LA Buse DC Lohr JB | 2001 | Biological Psychiatry2001，49，： | 1 |
| 15 | Metabolic effects of two years of exenatide treatment on diabetes, obesity, and hepatic bio- markers in patients with type 2 diabetes: an interim analysis of data from the open-label, uncontrolled extension of three double-blind, placebo-controlled trials显示文摘 | Buse JB Klonoff DC Nielsen LL | 2007 | Clin Ther2007，29，1： | 1 |
| 16 | Serum 1,5-anhydroglucitol (GlycoMark) : a short-term glycemic marker 显示文摘 | Buse JB Freeman JL Edelman SV | 2003 | Diabetes Technol Ther2003，5，3： | 1 |
| 17 | Exenatide onceweekly versus twice daily for the treatment of type 2 diabe-tes: a randomised,open-label, non-inferiority study 显示文摘 | Drucker DJ Buse JB Taylor K | 2008 | Lancet2008，372，9645： | 1 |
| 18 | Efficacy and safety of the humanglucagon-like peptide-1 analog liraglutide in combination with metformin andthiazolidinedione in patients with type 2 diabetes 显示文摘 | Zinman B Gerich J Buse JB | 2009 | Diabetes Care2009，32，： | 1 |
| 19 | Primary prevention of cardiovascular diseases in people with diabetes mellitus:ascientific statement from the American Heart Association and the American Diabetes Association显示文摘 | Buse JB Ginsberg HN Bakris GL | | 0，，01： | 1 |
| 20 | Liraglutide once a day versus exenatide twice a day for type 2 diabetes:a 26-week randomised,parallel-group,multinational,open-label trial(LEAD-6)显示文摘 | Buse JB Rosenstock J Sesti G | 2009 | Lancet2009，374，9683： | 1 |
您所在的机构暂未开通此部分的功能，请联系管理员